Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part of its growth strategy. Newer products in its drug lineup include a ...

The approvals were based on positive results from EV-302, in which Padcev plus Keytruda resulted in statistically significant ...

On Monday, Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...

Astellas Pharma has submitted a new drug application (NDA) to Japan's Ministry of Health, Labour and Welfare seeking conditional approval of avacincaptad pegol intravitreal solution (ACP ...

Enfortumab vedotin plus pembrolizumab cut the risk of death by 49% vs. chemo, with a median OS of 33.8 months vs. 15.9 months. The combination therapy reduced disease progression or death risk by ...